Tetra Bio-Pharma (TBP.T) received Health Canada’s approval for their amendment of a phase I study involving the safety profile of low and moderate doses of inhaled CBD. They’re conducting…
Search Results for: TBP.T
Not So Constipated Market I owe Flinstones Gummies my life. That’s a bit of an exaggeration, however, there’s no denying I cared more for my health as a kid…
Tetra Bio-Pharma (TBP.T) (“Tetra”) is a biopharmaceutical company focused on cannabinoid-derived drug discovery and development. The Company has an FDA and Health Canada cleared clinical program intended to bring…
Tetra Bio-Pharma (TBP.T) announced today that the Central Ethics Committee has approved the proposed protocol modifications allowing additional immediate release oral opioids to be used as a comparator in…
Tetra Bio-Pharma (TBP.T) announced today that the Central Ethics Committee has approved the proposed protocol modifications allowing additional immediate release oral opioids to be used as a comparator in…
Tetra Bio-Pharma (TBP.T) announced that their new investigation new drug (IND) ARDS-003 has been studied in a viral infected organoid model as part of a research collaboration between Targeted Pharmaceuticals…
Tetra Bio-Pharma (TBP.T) announced today that Health Canada has accepted the Company’s New Drug Submission (NDS) for REDUVO™ and has formally entered the final review phase in the drug…
Tetra Bio-Pharma (TBP.T) announced today that Health Canada has accepted the Company’s New Drug Submission (NDS) for REDUVO™ and has formally entered the final review phase in the drug…
Tetra Bio-Pharma (TBP.T) announced they are accelerating their PLENITUDE Phase II clinical trial, which is studying QIXLEEF. QIXLEEF is Tetra’s proprietary drug formulation which contains THC and CBD and…
Tetra Bio-Pharma (TBP.T) has announced the start of the REBORN1© clinical trial, designed to evaluate the effect of QIXLEEF™, the Company’s inhaled proprietary drug formulation. During this study, QIXLEEF™…